158P Neoadjuvant treatment in stage III NSCLC: Comparison with NADIM 2 trial as a gold standard by Casas, F., Redondo, M.G. Antelo, Sanchez-Lorente, D., Reyes, R., Martinez, D., Lucena, C., Vollmer, I., Cases, C., Mollá, M., Boada, M., Roig, M. Parera, Acosta, S. Castillo, Muñoz, S., Centella, C. Urbano, Guirao, A., Cobo, A., Benegas, M., Leon, F., Clavell, C., Segarra, N. Vinolas

Get full text